Rural Health
News by Topic: COVID-19

FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability Federal Register

Jul 29, 2025 - The Food and Drug Administration (FDA) has revoked Emergency Use Authorizations issued to Regeneron Pharmaceuticals, Inc., for REGEN-COV (casirivimab and imdevimab administered together); GlaxoSmithKline LLC for sotrovimab; Eli Lilly and Company for bebtelovimab; and AstraZeneca Pharmaceuticals LP for EVUSHELD (tixagevimab co-packaged with cilgavimab). These revocations are effective December 13, 2024.

view details